Formononetin inhibits p53 signaling pathway activation to delay cellular senescence and ameliorates diabetic kidney disease.

Yue Ji, Rui-Xin Liu, Pei-Yue He, Yi-Min Zhou, Ya-Chun Li, Jing Guo, Bo Nie, Yu-Ning Liu, Wei-Jing Liu

Institute of Nephrology & Beijing Key Laboratory, Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine, Beijing 100010, China.Institute of Nephrology & Beijing Key Laboratory, Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine, Beijing 100010, China. · pubmed

Paper

Abstract

Diabetic kidney disease (DKD) continues to pose a substantial public health challenge, in which cellular senescence is recognized as a pivotal driver of disease progression. While formononetin (FN) has been documented to exhibit anti-senescence properties, its potential as a therapeutic agent for DKD and the molecular mechanisms involved remain unexplored.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

Formononetin inhibits the p53 signaling pathway to delay cellular senescence and ameliorate diabetic kidney disease. The paper addresses the role of cellular senescence in disease progression, which is a key factor in aging and longevity research.

Author of this paper? Send a correction.